Journal of Clinical Endocrinology & Metabolism, Vol 78, 1202-1207, Copyright © 1994 by Endocrine Society

ARTICLES

Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma

M Davies, ME Hayes, JA Yin, JL Berry and EB Mawer
University Department of Medicine, Manchester Royal Infirmary, United Kingdom.

High serum concentrations of 1,25-dihydroxyvitamin D [1,25-(OH)2D] can occur with hypercalcemia in malignant lymphoma. We have investigated the potential for abnormal vitamin D metabolism by giving a single oral dose of 25-hydroxyvitamin D (25OHD) in 10 lymphoma patients (8 Hodgkin's and 2 T-cell) and 7 controls. Serum 25OHD increased similarly in both groups (peak concentrations, 114.1 +/- 9.5 vs. 123.9 +/- 9.6 nmol/L). In controls, serum calcium and PTH did not change after treatment [calcium, 2.31 +/- 0.02 and 2.33 +/- 0.02 mmol/L (mean +/- SEM); PTH, 21.6 +/- 4.0 and 25.4 +/- 4.3 ng/L] 1,25-(OH)2D increased within the normal range from [median (range)] 81 (48-125) to 117 (91- 156) pmol/L. In lymphoma patients, serum calcium increased from 2.29 +/- 0.04 to 2.40 +/- 0.06 mmol/L (P = 0.03), PTH decreased from 12.9 +/- 2.6 to 8.0 +/- 1.9 ng/L (P = 0.06), and one patient became hypercalcemic (2.92 mmol/L). Serum 1,25-(OH)2D became supranormal in 6 lymphoma patients; the group median rose from 74.5 (46-180) to 151 (120- 487) pmol/L; this peak response differed from that in the controls (P = 0.019). Lymph node and spleen cells from a patient with T-cell lymphoma synthesized [3H]1,25-(OH)2D3 from [3H] 25OHD3 in vitro. The data suggest that abnormal production of 1,25-(OH)2D in lymphoma may be more common than previously recognized given an adequate supply of precursor 25OHD and provide further evidence for the extrarenal synthesis of 1,25- (OH)2D in this condition.

This article has been cited by other articles:

				K. N. Evans, H. Taylor, D. Zehnder, M. D. Kilby, J. N. Bulmer, F. Shah, J. S. Adams, and M. Hewison Increased Expression of 25-Hydroxyvitamin D-1{alpha}-Hydroxylase in Dysgerminomas: A Novel Form of Humoral Hypercalcemia of Malignancy Am. J. Pathol., September 1, 2004; 165(3): 807 - 813. [Abstract] [Full Text] [PDF]

				R. M. Maas, K. Reus, B. Diesel, W.-I. Steudel, W. Feiden, U. Fischer, and E. Meese Amplification and Expression of Splice Variants of the Gene Encoding the P450 Cytochrome 25-Hydroxyvitamin D3 1,{{alpha}}-Hydroxylase (CYP 27B1) in Human Malignant Glioma Clin. Cancer Res., April 1, 2001; 7(4): 868 - 875. [Abstract] [Full Text]

				J. S. Adams and V. Kantorovich Inability of Short-Term, Low-Dose Hydroxychloroquine to Resolve Vitamin D-Mediated Hypercalcemia in Patients with B-Cell Lymphoma J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 799 - 801. [Abstract] [Full Text]

				T. M. Nguyen, J. Pavlovitch, M. Papiernik, H. Guillozo, O. Walrant-Debray, C. Pontoux, and M. Garabedian Changes in 1,25-(OH)2D3 Synthesis and Its Receptor Expression in Spleen Cell Subpopulations of Mice Infected with LPBM5 Retrovirus Endocrinology, December 1, 1997; 138(12): 5505 - 5510. [Abstract] [Full Text] [PDF]